India-based Lupin Pharmaceuticals has launched Fenofibrate tablets, 48 mg and 145 mg strengths in the US.
The company in the past has received the final approval for Fenofibrate tablets from the US Food and Drug Administration.
The released tablets are the AB rated generic, which is equal to Abbott's TRICOR tablets to treat primary Hypercholesterolemia or mixed Dyslipidemia and severe Hypertriglyceridemia.
Lupin Pharmaceuticals CEO and Lupin group president Vinita Gupta said the company is happy to make available the tablet in the US market.
''Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price," Gupta added.
According to IMS Health, Abbott's TRICOR had sales of $1.26bn in June 2012.
Lupin Pharmaceuticals is subsidiary of Lupin.
